| Literature DB >> 33256629 |
Techalew Shimelis1,2, Birkneh Tilahun Tadesse3, Fitsum W/Gebriel3, John A Crump4, Gill Schierhout5, Sabine Dittrich6,7, John M Kaldor8, Susana Vaz Nery8.
Abstract
BACKGROUND: The diagnosis of non-malarial aetiologies, which now represent the majority of febrile illnesses, has remained problematic in settings with limited laboratory capacity. We aimed to describe common aetiologies of acute febrile illness among children in a setting where malaria transmission has declined.Entities:
Keywords: Acute febrile illness; Aetiologies; Bacteraemia; Malaria; Urinary tract infection
Mesh:
Year: 2020 PMID: 33256629 PMCID: PMC7706267 DOI: 10.1186/s12879-020-05635-x
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Fig. 1Participant screening, enrolment, and laboratory investigations at HUCSH, 2018–2019. RDT, rapid diagnostic test; CSF, cerebrospinal fluid; GAS, group A Streptococcus. 1 Routinely available test. 2 Test available sometimes, but only for hospitalized patients with clinical indications. 3 Test available commonly, but only for hospitalized patients with clinical indications. 4 Test made available by the study
Demographic, anthropometric, and vaccination status of febrile children attending HUCSH, 2018–2019
| Characteristics | Frequency (%) |
|---|---|
| SNNPR-Hawassa | 258 (59.6) |
| SNNPR- other | 60 (13.9) |
| Oromia | 115 (26.6) |
| Male | 255 (58.9) |
| Female | 178 (41.1) |
| 2 to 11 m | 132 (30.5) |
| 12 to 35 m | 148 (34.2) |
| 36 to 59 m | 78 (18.0) |
| 5 to 7 y | 39 (9.0) |
| 8 to 12 y | 36 (8.3) |
| Vaccinated for age | 92 (21.2) |
| Completed | 318 (73.4) |
| Otherb | 23 (5.3) |
| Normal (≥ −2) | 318 (75.9) |
| Moderate underweight (−3 to < − 2) | 51 (12.2) |
| Severe underweight (< −3) | 50 (11.9) |
| Normal (≥ −2) | 342 (79.2) |
| Moderate stunting (−3 to < −2) | 42 (9.7) |
| Severe stunting (< −3) | 48 (11.1) |
| Normal (≥ −2) | 311 (72.0) |
| Moderate wasting (−3 to < −2) | 62 (14.4) |
| Severe wasting (< −3) | 59 (13.7) |
m months, y years
BMI body-mass-index
a Weight-for-age was calculated only for children up to 10 years of age
bPartially vaccinated (n = 9), unvaccinated (n = 11), unknown (n = 3)
Clinical history and presentation of children attending HUCSH, 2018–2019
| Characteristics | Frequency (%) ( |
|---|---|
| Chronic diseaseb | 16 (3.7) |
| Duration of fever | |
| 1 day | 118 (27.3) |
| 2–4 days | 239 (55.2) |
| 5–7 days | 76 (17.6) |
| Cough | 230 (53.1) |
| Vomiting | 160 (37.0) |
| Fast breathing | 79 (18.2) |
| Diarrhoea | 82 (18.9) |
| Headache | 24 (15.6)a |
| Sneezing /rhinorrhoea | 46 (10.6) |
| Sore throat | 16 (10.4)a |
| Grunting | 33 (7.6) |
| Abdominal pain | 28 (6.5) |
| Dysuria/urine frequency | 9 (2.1) |
| Rash | 9 (2.1) |
| Axillary temperature | |
| < 37.5 °C | 46 (10.6) |
| 37.5–38.9 °C | 325 (75.1) |
| ≥ 39 °C | 62 (14.3) |
| Tachypnea | 244 (56.4) |
| Tachycardia | 169 (39.0) |
| Throat | |
| Pharyngeal erythema | 55 (12.7) |
| Tonsillar enlargement | 48 (11.1) |
| Lung | |
| Retraction | 78 (18.0) |
| Chest indrawing | 35 (8.0) |
| Crepitation | 106 (24.5) |
| Abdomen | |
| Abdominal tenderness | 12 (2.8) |
| Hepatomegaly | 22 (5.1) |
| Lymphadenopathy | 12 (2.7) |
a Among children ≥3 years of age (N = 154)
b Chronic disease reported by caregiver [heart disease (n = 9), asthma (n = 2), seizure disorder (n = 1), tuberculosis (n = 1), epilepsy (n = 1), paralysis of limps (n = 1), right mandibular swelling (n = 1)]
Laboratory findings in febrile children attending HUCSH, 2018–2019
| Laboratory testing | Frequency (%) |
|---|---|
| Leukopenia | 41 (9.6) |
| Leukocytosis | 68 (15.9) |
| Neutrophilia | 62 (14.5) |
| Lymphocytosis | 2 (0.5) |
| Anaemia | 51 (11.9) |
| Malaria | 14 (3.2) |
| | 8 (1.8) |
| | 6 (1.4) |
| HIV | 3 (0.7) |
| 27 (6.4) | |
| | 16 (3.8) |
| | 4 (1.0) |
| Othera | 7 (1.6) |
| 74 (18.4) | |
| | 37 (9.2) |
| | 16 (4.0) |
| | 5 (1.2) |
| Otherb | 18 (4.5) |
| Microscopy | |
| | 2 (3.6) |
| | 1 (1.8) |
| Rotavirus /Adenovirus RDT | |
| Rotavirus | 14 (25) |
| Adenovirus | 4 (7.1) |
| Culture | |
| | 1 (1.8) |
| | 1 (1.8) |
| Throat swab ( | 28 (15.8) |
| Urine ( | 31 (17.0) |
| CSF ( | 1 (10) |
| Ear discharge ( | 1 (−) |
| CoNS | 1 (−) |
GAS group A Streptococcus, CSF cerebrospinal fluid, CoNS coagulase-negative staphylococci, RDT rapid diagnostic test
aHaemophilus parainfluenzae (n = 2), Haemophilus influenzae (n = 1), Enterrococcus species (n = 1), fungal cells (n = 3)
bProteus vulgaris (n = 3), Morganella morganii (n = 3), Enterococcus species (n = 3), Providencia rettgeri (n = 2), Pseudomonas species (n = 2), Citrobacter species (n = 2), Streptococcus pyogenes (n = 1), Staphyloccocus saprophyticus (n = 1), Streptococcus agalactiae (n = 1)
c The total number of children tested (N) varied as inadequate or no sample was obtained for some children
Antimicrobial susceptibility pattern of bacteria isolated from various samples in febrile children attending HUCSH, 2018–2019
| Name of antimicrobial | Other Gram-negative | Other Gram-positive (n/N) | All isolates | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Susceptible | Resistant | Susceptible | Resistant | Susceptible | Resistant | Susceptible | Resistant | Susceptible | Resistant | Susceptible | Resistant | |
| Ampicillin | 0 (0) | 37 (97.4) | 1 (5.3)b | 18 (90.0)b | 4 (28.6)d | 10 (71.4)d | – | – | (1/4) | (3/4) | 6 (8.0)m | 68 (90.7)m |
| Trimethoprim-sulfamethoxazole | 3 (7.9) | 35 (92.1) | 3 (15.0) | 17 (85.0) | 4 (26.7) | 11 (73.3) | 7 (33.3) | 14 (66.7) | (0/1) | (1/1) | 17 (17.9)p | 78 (82.1)p |
| Tetracycline | 6 (15.8) | 30 (78.9) | 5 (25.0) | 14 (70.0) | 5 (35.7)d | 7 (50.0)d | 3 (15.0)k | 16 (80.0)k | (0/4) | (4/4) | 19 (19.8)q | 71 (74.0)q |
| Amoxicillin and clavulanic acid | 8 (21.1) | 26 (68.4) | 4 (20.0) | 10 (50.0) | 6 (42.9)d | 7 (50.0)d | – | – | – | – | 18 (25.0)r | 43 (59.7)r |
| Ceftriaxone | 14 (36.8) | 20 (52.6) | 7 (35.0) | 13 (65.0) | 7 (53.8)e | 4 (30.8)e | – | – | (0/1) | (1/1) | 28 (38.9)r | 38 (52.8)r |
| Ceftazidime | 15 (39.5) | 21 (55.3) | 5 (25.0) | 13 (65.0) | 9 (60.0) | 5 (33.3) | – | – | – | – | 29 (39.7)t | 39 (53.4)t |
| Gentamicin | 23 (60.5) | 14 (36.8) | 8 (40.0) | 12 (60.0) | 7 (63.6)f | 4 (36.4)f | 15 (71.4) | 5 (23.8) | (4/5) | (1/5) | 57 (60.0)p | 36 (37.9)p |
| Chloramphenicol | 23 (60.5) | 15 (39.5) | 9 (45.0) | 11 (55.0) | 9 (64.3)d | 2 (14.3)d | 18 (85.7) | 3 (14.3) | (2/2) | 0 | 61 (64.2)p | 31 (32.6)p |
| Ciprofloxacin | 26 (68.4) | 8 (21.1) | 15 (75.0) | 1 (5.0) | 13 (86.7) | 1 (6.7) | 16 (76.2) | 4 (19.0) | (3/4) | 0 | 73 (74.5)u | 14 (14.3)u |
| Meropenem | 33 (86.8) | 2 (5.3) | 16 (80.0) | 1 (5.0) | 7 (46.7) | 2 (13.3) | – | – | – | – | 56 (76.7)t | 5 (6.8)t |
| Nitrofurantoin* | 37 (100)a | 0 (0) | 15 (93.8)c | 0 (0) | 7 (87.5)g | 1 (12.5)g | 5 (100)h | 0 (0) | (4/4) | 0 | 68 (97.1)w | 1 (1.4)w |
| Norfloxacin* | 27 (73.0)a | 9 (24.3)a | 14 (87.5)c | 1 (5.0)c | 10 (90.9)f | 1 (9.1)f | 4 (80.0)h | 1 (20.0)h | (3/4) | (1/4) | 58 (79.5)t | 13 (17.8)t |
| Penicillin G | – | – | – | 3 (15.0)k | 17 (85.0)k | (2/5) | (3/5) | 5 (20.0)x | 20 (80.0)x | |||
| Erythromycin | – | – | – | 10 (47.6) | 11 (52.4) | (1/2) | (1/2) | 11 (47.8)y | 12 (52.2)y | |||
| Cefoxitin | – | – | – | 13 (61.9) | 7 (33.3) | (1/1) | 0 | 14 (63.6)z | 7 (31.8)z | |||
| Clindamycin | – | – | – | 17 (81.9) | 4 (19.0) | (1/2) | (1/2) | 18 (78.3)y | 5 (21.7)y | |||
*Tested for urine isolates as recommended by the guideline
Number of given isolates tested for the antimicrobials: E.coli: a(N = 37); Klebsiella species: b(N = 19), c(N = 16); Other Gram-negative bacteria: d(N = 14), e(N = 13), f(N = 11), g(N = 8); S. aureus: h(N = 5), k(N = 20)
¶ Each type of isolate was tested for subsets of antimicrobials as recommended by the guideline; there are few missing cases: m(N = 75), p(N = 95), q(N = 96), r(N = 72) t(N = 73), u(N = 98), w(N = 70), x(N = 25), y(N = 23), z(N = 22)